Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (vol 401, pg 1655, 2023)

被引：1
|
作者：
Shitara, K.
Lordick, F.
Bang, Y-J
机构：
来源：
LANCET | 2023年 / 402卷 / 10398期
关键词：
D O I：
10.1016/S0140-6736(23)01481-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：290 / 290
页数：1
相关论文
共 33 条
  • [1] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial
    Shitara, Kohei
    Lordick, Florian
    Bang, Yung-Jue
    Enzinger, Peter
    Ilson, David
    Shah, Manish A.
    Van Cutsem, Eric
    Xu, Rui-Hua
    Aprile, Giuseppe
    Xu, Jianming
    Chao, Joseph
    Pazo-Cid, Roberto
    Kang, Yoon-Koo
    Yang, Jianning
    Moran, Diarmuid
    Bhattacharya, Pranob
    Arozullah, Ahsan
    Park, Jung Wook
    Oh, Mok
    Ajani, Jaffer A.
    LANCET, 2023, 401 (10389): : 1655 - 1668
  • [2] Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
    Huang, Yufan
    You, Maojin
    Wu, Qundan
    Chen, Ruijia
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas
    Shitara, Kohei
    Yamaguchi, Kensei
    Shoji, Hirokazu
    Matsangou, Maria
    Bhattacharya, Pranob P.
    Park, Jung Wook
    Klempner, Samuel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
    Kang, Yoon-Koo
    Chen, Li-Tzong
    Ryu, Min-Hee
    Oh, Do-Youn
    Oh, Sang Cheul
    Chung, Hyun Cheol
    Lee, Keun-Wook
    Omori, Takeshi
    Shitara, Kohei
    Sakuramoto, Shinichi
    Chung, Ik-Joo
    Yamaguchi, Kensei
    Kato, Ken
    Sym, Sun Jin
    Kadowaki, Shigenori
    Tsuji, Kunihiro
    Chen, Jen-Shi
    Bai, Li-Yuan
    Oh, Sung-Yong
    Choda, Yasuhiro
    Yasui, Hisateru
    Takeuchi, Kentaro
    Hirashima, Yoshinori
    Hagihara, Shunsuke
    Boku, Narikazu
    LANCET ONCOLOGY, 2022, 23 (02): : 234 - 247
  • [5] Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.
    Klempner, Samuel J.
    Lee, Keun-Wook
    Metges, Jean-Philippe
    Catenacci, Daniel V. T.
    Loupakis, Fotios
    Ilson, David H.
    Shah, Manish A.
    Shitara, Kohei
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable advanced or recurrent gastric, gastroesophageal junction cancer or esophageal adenocarcinoma (GENTLE-Z).
    Okunaka, Mashiro
    Furuoka, Momoka
    Wakabayashi, Masashi
    Furuya, Hideki
    Bando, Hideaki
    Shitara, Kohei
    Nakayama, Izuma
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS504 - TPS504
  • [7] Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    Wilke, Hansjochen
    Muro, Kei
    Van Cutsem, Eric
    Oh, Sang-Cheul
    Bodoky, Gyoergy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg
    Kim, Tae-You
    Cunningham, David
    Rougier, Philippe
    Komatsu, Yoshito
    Ajani, Jaffer
    Emig, Michael
    Carlesi, Roberto
    Ferry, David
    Chandrawansa, Kumari
    Schwartz, Jonathan D.
    Ohtsu, Atsushi
    LANCET ONCOLOGY, 2014, 15 (11): : 1224 - 1235
  • [8] Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial
    Leitner, H.
    TUMORBOARD, 2015, 4 (01): : 18 - 19
  • [9] SPOTLIGHT: Comparison of zolbetuximab or placebo+mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
    Yamaguchi, K.
    Shitara, K.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Lordick, F.
    Shah, M.
    Van Cutsem, E.
    Xu, R-H.
    Arozullah, A.
    Park, J. Wook
    Ajani, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study
    Lordick, F.
    Shitara, K.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Aprile, G.
    Xu, J.
    Chao, J.
    Pazo-Cid, R.
    Kang, Y. K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 115 - 116
1234